Gemcitabine, Doxorubicin and Paclitaxel (GAT) as Neoadjuvant Treatment of Breast Cancer Patients

Inclusion Criteria: * Stage III breast cancer disease, with histological confirmation by true-cut or open-biopsy. * Ages between 18 and 75 years old. Patients older than 70 must have an adequate quality of life to be eligible. * Patients cannot have received previous treatment with chemotherapy, hormone therapy, radiotherapy or immune therapy. * Performance status of 0,1, 2 Eastern Cooperative Oncology Group (ECOG). * At least a 6 month life expectancy. * Neutrophils \> 1500; platelets \> 100000; haemoglobin \> 10 mg/dL. * Adequate renal and hepatic functions, with serum creatinine \< 1.2 mg/dl and total bilirubin \< 2 mg/dl. * Adequate contraceptive methods during the study and up to 3 months after. * Adequate cardiac function assessed by physical exam, electrocardiogram and left ventricular ejection fraction \> 55%. Exclusion Criteria: * Inflammatory carcinoma or stage I, II or IV breast cancer disease. * Males. * Active infection. * Other neoplasms except for basal skin carcinoma or cervical in situ carcinoma adequately treated. Other previous neoplasms are allowed if diagnosed and treated more than 5 years before study registration. * Concomitant serious disease provoking organ failure (heart, renal, hepatic, respiratory). * Pre-existing motor or sensorial neuropathy \> grade 1. * Inability for treatment compliance. * History of hypersensitivity to compounds such as cremophor, cyclosporine or vitamin K. * History of arrhythmias or congestive heart failure, even when controlled; or active cardiac blocking of second or third grade. * History of myocardial infarction in the previous 6 months. * Hypertension not controlled. * Pregnant or lactating women.